Search

Your search keyword '"Cagatay, Y"' showing total 26 results
Start Over Author "Cagatay, Y"
26 results on '"Cagatay, Y"'

7. Assessment of the New 2012 EULAR/ACR Clinical Classification Criteria

Author

Ozen, G, Inanc, N, Unal, AU, Bas, S, Kimyon, G, Kisacik, B, Onat, AM, Murat, S, Keskin, H, Can, M, Mengi, A, Cakir, N, Balkarli, A, Cobankara, V, Yilmaz, N, Yazici, A, Dogru, A, Sahin, M, Sahin, A, Gok, K, Senel, S, Pamuk, ON, Yilmaz, S, Bayindir, O, Aksu, K, Cagatay, Y, Akyol, L, Sayarlioglu, M, Yildirim-Cetin, G, Yasar-Bilge, S, Yagci, I, Aydin, SZ, Alibaz-Oner, F, Atagunduz, P, and Direskeneli, H

Subjects
musculoskeletal diseases, education, POLYMYALGIA RHEUMATICA, CLASSIFICATION CRITERIA, RHEUMATOID ARTHRITIS
Abstract

Objective. To assess the performance of the new 2012 provisional European League Against Rheumatism (EULAR)/ American College of Rheumatology (ACR) polymyalgia rheumatica (PMR) clinical classification criteria in discriminating PMR from other mimicking conditions compared with the previous 5 diagnostic criteria in a multicenter prospective study. Methods. Patients older than 50 years, presenting with new-onset bilateral shoulder pain with elevated acute-phase reactants (APR), were assessed for the fulfillment of the new and old classification/diagnostic criteria sets for PMR. At the end of the 1-year followup, 133 patients were diagnosed with PMR (expert opinion) and 142 with non-PMR conditions [69 rheumatoid arthritis (RA)]. Discriminating capacity, sensitivity, and specificity of the criteria sets were estimated. Results. Discriminating capacity of the new clinical criteria for PMR from non-PMR conditions and RA as estimated by area under the curve (AUC) were good with AUC of 0.736 and 0.781, respectively. The new criteria had a sensitivity of 89.5% and a specificity of 57.7% when tested against all non-PMR cases. When tested against all RA, seropositive RA, seronegative RA, and non-RA control patients, specificity changed to 66.7%, 100%, 20.7%, and 49.3%, respectively. Except for the Bird criteria, the 4 previous criteria had lower sensitivity and higher specificity (ranging from 83%-93%) compared with the new clinical criteria in discriminating PMR from all other controls. Conclusion. The new 2012 EULAR/ ACR clinical classification criteria for PMR is highly sensitive; however, its ability to discriminate PMR from other inflammatory/noninflammatory shoulder conditions, especially from seronegative RA, is not adequate. Imaging and other modifications such as cutoff values for APR might increase the specificity of the criteria.

Published
2016

8. related factors of patients with adult-onset Still's disease: Data from

Author

Kalyoncu, U, Solmaz, D, Emmungil, H, Yazici, A, Kasifoglu, T, Kimyon, G, Balkarli, A, Bes, C, Ozmen, M, Alibaz-Oner, F, Erten, S, Cagatay, Y, Cetin, GY, Yilmaz, S, Yildiz, F, Pamuk, ON, Kucuksahin, O, Kilic, L, Yazisiz, V, Karadag, O, Koca, SS, Hayran, M, Akar, S, Aksu, K, Akkoc, N, Keser, G, Gonullu, E, Kisacik, B, Onat, AM, Soy, M, Inanc, N, Direskeneli, H, Sayarlioglu, M, Erken, E, Turgay, M, Cefle, A, Ertenli, I, and Pay, S

Subjects
Adult-onset Still's disease, Disease modifying anti-rheumatic drugs, Disease pattern, Remission
Abstract

Background: Adult-onset Still's disease (AOSD) is a rare condition, and treatment choices are frequently dependent on expert opinions. The objectives of the present study were to assess treatment modalities, disease course, and the factors influencing the outcome of patients with AOSD. Methods: A multicenter study was used to reach sufficient patient numbers. The diagnosis of AOSD was based on the Yamaguchi criteria. The data collected included patient age, gender, age at the time of diagnosis, delay time for the diagnosis, typical AOSD rash, arthralgia, arthritis, myalgia, sore throat, lymphadenopathy, hepatomegaly, splenomegaly, pleuritic, pericarditis, and other rare findings. The laboratory findings of the patients were also recorded. The drugs initiated after the establishment of a diagnosis and the induction of remission with the first treatment was recorded. Disease patterns and related factors were also investigated. A multivariate analysis was performed to assess the factors related to remission. Results: The initial data of 356 patients (210 females; 59%) from 19 centers were evaluated. The median age at onset was 32 (16-88) years, and the median follow-up time was 22 months (0-180). Fever (95.8%), arthralgia (94.9%), typical AOSD rash (66.9%), arthritis (64.6%), sore throat (63.5%), and myalgia (52.8%) were the most frequent clinical features. It was found that 254 of the 306 patients (83.0%) displayed remission with the initial treatment, including corticosteroids plus methotrexate with or without other disease-modifying antirheumatic drugs. The multivariate analysis revealed that the male sex, delayed diagnosis of more than 6 months, failure to achieve remission with initial treatment, and arthritis involving wrist/elbow joints were related to the chronic disease course. Conclusion: Induction of remission with initial treatment was achieved in the majority of AOSD patients. Failure to achieve remission with initial treatment as well as a delayed diagnosis implicated a chronic disease course in AOSD. (C) 2016 Elsevier Ltd. All rights reserved.

Published
2016

9. amyloidosis in Turkish rheumatoid arthritis and ankylosing spondylitis

Author

Pamuk, ON, Kalyoncu, U, Aksu, K, Omma, A, Pehlivan, Y, Cagatay, Y, Kucuksahin, O, Donmez, S, Cetin, GY, Mercan, R, Bayindir, O, Cefle, A, Yildiz, F, Balkarli, A, Kilic, L, Cakir, N, Kisacik, B, Oksuz, MF, Cobankara, V, Onat, AM, Sayarlioglu, M, Ozturk, MA, Pamuk, GE, and Akkoc, N

Subjects
Secondary amyloidosis, Rheumatoid arthritis, Ankylosing spondylitis, Biologic therapy, Anti-TNF
Abstract

In this multicenter, retrospective study, we evaluated the efficacy and safety of biologic therapies, including anti-TNFs, in secondary (AA) amyloidosis patients with ankylosing spondylitis (AS) and rheumatoid arthritis (RA). In addition, the frequency of secondary amyloidosis in RA and AS patients in a single center was estimated. Fifty-one AS (39M, 12F, mean age: 46.7) and 30 RA patients (11M, 19F, mean age: 51.7) with AA amyloidosis from 16 different centers in Turkey were included. Clinical and demographical features of patients were obtained from medical charts. A composite response index (CRI) to biologic therapy-based on creatinine level, proteinuria and disease activity-was used to evaluate the efficacy of treatment. The mean annual incidence of AA amyloidosis in RA and AS patients was 0.23 and 0.42/1000 patients/year, respectively. The point prevalence in RA and AS groups was 4.59 and 7.58/1000, respectively. In RA group with AA amyloidosis, effective response was obtained in 52.2 % of patients according to CRI. RA patients with RF positivity and more initial disease activity tended to have higher response rates to therapy (p values, 0.069 and 0.056). After biologic therapy (median 17 months), two RA patients died and two developed tuberculosis. In AS group, 45.7 % of patients fulfilled the criteria of good response according to CRI. AS patients with higher CRP levels at the time of AA diagnosis and at the beginning of anti-TNF therapy had higher response rates (p values, 0.011 and 0.017). During follow-up after anti-TNF therapy (median 38 months), one patient died and tuberculosis developed in two patients. Biologic therapy seems to be effective in at least half of RA and AS patients with AA amyloidosis. Tuberculosis was the most important safety concern.

Published
2016

10. Association of TRPM Channel Gene Polymorphisms with Systemic Sclerosis

Author

Oztuzcu, S., Onat, A. M., Pehlivan, Y., Alibaz-Oner, F., Donmez, S., Cetin, G. Y., Yolbas, S., ibrahim bozgeyik, Yilmaz, N., Ozgen, M., Cagatay, Y., Kisacik, B., Koca, S. S., Pamuk, O. N., Sayarlioglu, M., Direskeneli, H., and Demiryurek, A. T.

Abstract

Background/Aim: Systemic sclerosis (SSc) is an inflammatory disease characterized by vascular abnormalities and fibrosis. The aim of the present study was to investigate the possible role of transient receptor potential melastatin (TRPM) channel genes in the susceptibility and phenotype expression of SSc. Materials and Methods: A total of 339 patients with SSc and 302 healthy controls were studied. Genomic DNA was extracted from leukocytes of the peripheral blood, and 25 single nucleotide polymorphisms in the TRPM channel genes were analyzed by the BioMark HD dynamic array system. Results: There were marked increases in the CC genotype (94.7% vs 81.8%, p

Published
2015

11. Therapeutic Regimens on the Incidence of New Relapses

Author

Alibaz-Oner, F, Karadeniz, A, Yilmaz, S, Balkarli, A, Kimyon, G, Yazici, A, Cinar, M, Yildiz, F, Bilge, SY, Bilgin, E, Coskun, BN, Omma, A, Cetin, GY, Cagatay, Y, Karaaslan, Y, Sayarlioglu, M, Pehlivan, Y, Kalyoncu, U, Karadag, O, Kasifoglu, T, Erken, E, Pay, S, Cefle, A, Kisacik, B, Onat, AM, Cobankara, V, and Direskeneli, H

Abstract

Vascular involvement is one of the major causes of mortality and morbidity in Behcet disease (BD). There are no controlled studies for the management of vascular BD (VBD), and according to the EULAR recommendations, only immunosuppressive (IS) agents are recommended. In this study, we aimed to investigate the therapeutic approaches chosen by Turkish physicians during the initial event and relapses of VBD and the association of different treatment options with the relapses retrospectively. Patients with BD (n = 936, female/male: 347/589, mean age: 37.6 +/- 10.8) classified according to ISG criteria from 15 rheumatology centers in Turkey were included. The demographic data, clinical characteristics of the first vascular event and relapses, treatment protocols, and data about complications were acquired.

Published
2015

12. Poster session 1: Wednesday 3 December 2014, 09:00-16:00Location: Poster area

Author

Tong, L., Huang, C., Ramalli, A., Tortoli, P., Luo, J., D'Hooge, J., Tzemos, N., Mordi, I., Bishay, T., Negishi, T., Hristova, K., Kurosawa, K., Bansal, M., Thavendiranathan, P., Yuda, S., Popescu, B., Vinereanu, D., Penicka, M., Marwick, T., Hamed, W., Kamel, M., Yaseen, R., El Barbary, H., Nemes, A., Kis, O., Gavaller, H., Kanyo, E., Forster, T., Angelis, A., Vlachopoulos, C., Ioakimidis, N., Felekos, I., Chrysohoou, C., Aznaouridis, K., Abdelrasoul, M., Terentes, D., Ageli, K., Stefanadis, C., Kurnicka, K., Domienik Karlowicz, J., Lichodziejewska, B., Goliszek, S., Grudzka, K., Krupa, M., Dzikowska Diduch, O., Ciurzynski, M., Pruszczyk, P., Capllonch, F. G., Ayerbe, J. L., Teis, A., Ferrer, E., Vallejo, N., Junca, G., Pla, R., Bayes Genis, A., Schwaiger, J., Knight, D., Gallimore, A., Schreiber, B., Handler, C., Coghlan, J., Bruno, R. M., Giardini, G., Malacrida, S., Catuzzo, B., Armenia, S., Brustia, R., Ghiadoni, L., Cauchy, E., Pratali, L., Kim, K., Lee, K., Cho, J., Yoon, H., Ahn, Y., Jeong, M., Park, J., Cho, S., Nastase, O., Enache, R., Mateescu, A., Botezatu, D., Ginghina, C., Gu, H., Sinha, M., Simpson, J., Chowienczyk, P., Fazlinezhad, A., Behesthi, A. T., Homaei, F., Mostafavi, H., Hosseini, G., Bakaeiyan, M., Boutsikou, M., Petrou, E., Dimopoulos, A., Dritsas, A., Leontiadis, E., Karatasakis, G., Sahin, S. T., Yurdakul, S., Yilmaz, N., Cengiz, B., Cagatay, Y., Aytekin, S., Yavuz, S., Karlsen, S., Dahlslett, T., Grenne, B., Sjoli, B., Smiseth, O., Edvardsen, T., Brunvand, H., Nasr, G., Nasr, A., Eleraki, A., Elrefai, S., Sonecki, P., Gustafsson, U., Naar, J., Stahlberg, M., Cerne, A., Capotosto, L., Rosato, Edoardo, D'Angeli, I., Azzano, A., Truscelli, G., Maio, M. D., Salsano, F., Terzano, C., Mangieri, E., Vitarelli, A., Renard, S., Najih, H., Mancini, J., Jacquier, A., Haentjens, J., Gaubert, J., Habib, G., Caminiti, G., D'Antoni, V., Cardaci, V., Conti, V., Volterrani, M., Ahn, J., Kim, D., Lee, H., Iliuta, L., Kim, S., Ryu, S., Ko, C., Pyun, Y., Yoon, S., Iudice, F. L., Esposito, R., Lembo, M., Santoro, C., Ballo, P., Mondillo, S., Simone, G. D., Galderisi, M., Hwang, Y., Kim, J., Moon, K., Yoo, K., Kim, C., Tagliamonte, E., Rigo, F., Cirillo, T., Caruso, A., Astarita, C., Cice, G., Quaranta, G., Romano, C., Capuano, N., Calabro', R., Zagatina, A., Zhuravskaya, N., Guseva, O., Huttin, O., Benichou, M., Voilliot, D., Venner, C., Micard, E., Girerd, N., Sadoul, N., Moulin, F., Juilliere, Y., Selton Suty, C., Baron, T., Christersson, C., Johansson, K., Flachskampf, F., Lee, S., Lee, J., Hur, S., Yun, J., Song, S., Kim, W., Ko, J., Nyktari, E., Bilal, S., Ali, S., Izgi, C., Prasad, S., Aly, M., Kleijn, S., Kandil, H., Kamp, O., Beladan, C., Calin, A., Rosca, M., Craciun, A., Gurzun, M., Calin, C., Mornos, C., Mornos, A., Ionac, A., Cozma, D., Crisan, S., Popescu, I., Ionescu, G., Petrescu, L., Camacho, S., Chulian, S. G., Carmona, R., Diaz, E., Giraldez, A., Gutierrez, A., Toro, R., Benezet, J., Antonini Canterin, F., Vriz, O., Carrubba, S. L., Poli, S., Leiballi, E., Zito, C., Careri, S., Caruso, R., Pellegrinet, M., Nicolosi, G., Kong, W., Kyu, K., Wong, R., Tay, E., Yip, J., Yeo, T., Poh, K., Correia, M., Delgado, A., Marmelo, B., Correia, E., Abreu, L., Cabral, C., Gama, P., Santos, O., Rahman, M., Borges, I. P., Peixoto, E., Peixoto, R., Marcolla, V., Okura, H., Kanai, M., Murata, E., Kataoka, T., Stoebe, S., Tarr, A., Pfeiffer, D., Hagendorff, A., Generati, G., Bandera, F., Pellegrino, M., Alfonzetti, E., Labate, V., Guazzi, M., Kuznetsov, V., Yaroslavskaya, E., Pushkarev, G., Krinochkin, D., Zyrianov, I., Carigi, S., Baldazzi, F., Bologna, F., Amati, S., Venturi, P., Grosseto, D., Biagetti, C., Fabbri, E., Arlotti, M., Piovaccari, G., Rahbi, H., Abdulhaq, A. B., Tleyjeh, I., Costantino, M., Tarsia, G., Innelli, P., Dores, E., Esposito, G., Matera, A., Trimarco, B., Mukred, K., Ashurov, R., Tanzilli, G., Merlo, M., Gigli, M., Stolfo, D., Pinamonti, B., Canterin, F. A., Muca, M., D'Angelo, G., Scapol, S., Nucci, M. D., Sinagra, G., Behaghel, A., Feneon, D., Fournet, M., Thebault, C., Martins, R., Mabo, P., Leclercq, C., Daubert, C., Donal, E., Pal, S. D., Chand, N. P., Sanjeev, A., Rajeev, M., Ankur, D., Gopal, S. R., Mzoughi, K., Zairi, I., Jabeur, M., Moussa, F. B., Chaabene, A. B., Kamoun, S., Mrabet, K., Fennira, S., Zargouni, A., Kraiem, S., Demkina, A., Hashieva, F., Krylova, N., Kovalevskaya, E., Potehkina, N., Zaroui, A., Said, R. B., Smaali, S., Rekik, B., Hlima, M. B., Mizouni, H., Mechmeche, R., Mourali, M., Malhotra, A., Sheikh, N., Dhutia, H., Siva, A., Narain, R., Merghani, A., Millar, L., Walker, M., Sharma, S., Papadakis, M., Siam Tsieu, V., Mansencal, N., Arslan, M., Deblaise, J., Dubourg, O., Boudiche, S., Larbi, N., Tababi, N., Hannachi, S., Chalbia, T., Halima, M. B., Boussada, R., Chistyakova, M. V., Govorin, A., Radaeva, E., Lipari, P., Bonapace, S., Valbusa, F., Rossi, A., Zenari, L., Lanzoni, L., Targher, G., Canali, G., Molon, G., Barbieri, E., Novo, G., Giambanco, S., Sutera, M., Bonomo, V., Giambanco, F., Rotolo, A., Evola, S., Assennato, P., Novo, S., Budnik, M., Piatkowski, R., Kochanowski, J., Opolski, G., Chatzistamatiou, E., Vagena, I. M., Manakos, K., Moustakas, G., Konstantinidis, D., Memo, G., Mitsakis, O., Kasakogias, A., Syros, P., Kallikazaros, I., Park, S., Kim, M., Shim, W., Marketou, M., Parthenakis, F., Kalyva, N., Pontikoglou, C., Maragkoudakis, S., Zacharis, E., Patrianakos, A., Maragoudakis, F., Papadaki, H., Vardas, P., Rodrigues, A., Perandini, L. A., Souza, T., Sa Pinto, A., Borba, E., Arruda, A., Furtado, M., Carvalho, F., Bonfa, E., Andrade, J., Hlubocka, Z., Malinova, V., Palecek, T., Danzig, V., Kuchynka, P., Dostalova, G., Zeman, J., Linhart, A., Trachanas, K., Vergi, N., Feretou, A., Corut, H., Sade, L. E., Ozin, B., Atar, I., Turgay, O., Muderrisoglu, H., Ledakowicz Polak, A., Polak, L., Krauza, G., Zielinska, M., Szulik, M., Streb, W., Wozniak, A., Lenarczyk, R., Sliwinska, A., Kalarus, Z., Kukulski, T., Nogueira, M., Branco, L., Agapito, A., Galrinho, A., Borba, A., Teixeira, P., Monteiro, A., Ramos, R., Cacela, D., Ferreira, R. C., Guala, A., Camporeale, C., Tosello, F., Canuto, C., Ridolfi, L., Traxanas, K., Marinov, R., Stamenov, G., Mihova, M., Persenska, S., Racheva, A., Plaskota, K., Trojnarska, O., Bartczak, A., Grajek, S., Bejiqi, R. R., Retkoceri, R., Bejiqi, H., Beha, A., Surdulli, S., Seya, M., Sasaoka, T., Hirasawa, K., Yoshikawa, S., Maejima, Y., Ashikaga, T., Hirao, K., Isobe, M., Dreyfus, J., Durand Viel, G., Cimadevilla, C., Brochet, E., Vahanian, A., Messika Zeitoun, D., Jin, C., Fang, F., Meng, F., Kam, K., Sun, J., Tsui, G., Wong, K., Wan, S., Yu, C., Lee, A., Cho, I. J., Chung, H., Heo, R., Ha, S., Hong, G., Shim, C., Chang, H., Ha, J., Chung, N., Moral, S., Gruosso, D., Galuppo, V., Teixido, G., Rodriguez Palomares, J., Gutierrez, L., Evangelista, A., Alexopoulos, A., Dawson, D., Nihoyannopoulos, P., Zainal, H. A., Ismail, J., Arshad, K., Ibrahim, Z., Lim, C., Rahman, E. A., Kasim, S., Peteiro, J., Barrio, A., Escudero, A., Bouzas Mosquera, A., Yanez, J., Martinez, D., Castro Beiras, A., Scali, M., Simioniuc, A., Mandoli, G., Lombardo, A., Massaro, F., Bello, V. D., Marzilli, M., Dini, F., Adachi, H., Tomono, J., Oshima, S., Ortega, G. M., Bustos, D. B., Garcia, R. L., Espino, A. S., Quinones, J. M., Ikuta, I., Lopez, M. R., Serrano, F. V., Gonzalez, J. B., Recio, M. G., Romano, G., D'Ancona, G., Pilato, G., Gesaro, G. D., Clemenza, F., Raffa, G., Scardulla, C., Sciacca, S., Lancellotti, P., Pilato, M., Addetia, K., Takeuchi, M., Maffessanti, F., Weinert, L., Hamilton, J., Mor Avi, V., Lang, R., Sugano, A., Seo, Y., Watabe, H., Kakefuda, Y., Aihara, H., Nishina, H., Ishizu, T., Fumikura, Y., Noguchi, Y., Aonuma, K., Luo, X., Shang, Q., Sammut, E. C., Chabinok, R., Jackson, T., Siarkos, M., Lee, L., Carr White, G., Rajani, R., Kapetanakis, S., Byrne, D., Walsh, J., Ellis, L., Mckiernan, S., Norris, S., King, G., Murphy, R., Katova, T., Simova, I., Kostova, V., Shuie, I., Ferferieva, V., Bogdanova, V., Castelon, X., Sasi, V., Domsik, P., Kalapos, A., Lengyel, C., Orosz, A., Grapsa, J., Demir, O., Sharma, R., Senior, R., Pilichowska, E., Zaborska, B., Baran, J., Stec, S., Kulakowski, P., Budaj, A., Herrera, J. E., Palacios, I. F., Mendoza, I., Marquez, J. A., Herrera, J. A., Octavio, J. A., Dempaire, G., Rotolo, M., Kosmala, W., Kaye, G., Saito, M., Negishi, K., Maceira, A. M., Ripoll, C., Cosin Sales, J., Igual, B., Salazar, J., Belloch, V., Dulai, R. S., Taylor, A., Gupta, S., and S. U. C., None

Published
2014

13. FRI0265 Validation of New 2012 EULAR/ACR Clinical Classification Criteria for Polymyalgia Rheumatica: Comparison with the Previous Criteria in a Prospective Multi-Center Study

Author

Ozen, G., primary, Bas, S., additional, Unal, A.U., additional, Kimyon, G., additional, Onat, A.M., additional, Murat, S., additional, Keskin, H., additional, Sahin, A., additional, Can, M., additional, Mengi, A., additional, Yilmaz, S., additional, Balkarli, A., additional, Cobankara, V., additional, Pamuk, O.N., additional, Cagatay, Y., additional, Bayindir, O., additional, Aksu, K., additional, Alibaz-Oner, F., additional, Gok, K., additional, Senel, S., additional, Yilmaz, N., additional, Yildirim-Cetin, G., additional, Akyol, L., additional, Sayarlioglu, M., additional, Yagci, I., additional, Atagunduz, P., additional, Aydin, S.Z., additional, Inanc, N., additional, and Direskeneli, H., additional

Published
2015
Full Text
View/download PDF

14. THU0491 Delay of Diagnosis in Still’s Disease is Associated with a Chronic/Relapsing Pattern: National, Multicenter Study of 356 Patients

Author

Kalyoncu, U., primary, Solmaz, D., additional, Emmungil, H., additional, Yazici, A., additional, Kasifoglu, T., additional, Kimyon, G., additional, Ayan, A., additional, Bes, C., additional, Ozmen, M., additional, Oner, F. A., additional, Erten, S., additional, Cagatay, Y., additional, Cetin, G. Y., additional, Yilmaz, S., additional, Yildiz, F., additional, Pamuk, O. N., additional, Kucuksahin, O., additional, Yazisiz, V., additional, Karadag, O., additional, Koca, S. S., additional, Akar, S., additional, Aksu, K., additional, Akkoc, N., additional, Keser, G., additional, Gonullu, E., additional, Kisacik, B., additional, Onat, A. M., additional, Soy, M., additional, Inanc, N., additional, Direskeneli, H., additional, Sayarlioglu, M., additional, Erken, E., additional, Turgay, M., additional, Cefle, A., additional, Haznedaroglu, S., additional, Mercan, R., additional, Ertenli, I., additional, and Pay, S., additional

Published
2013
Full Text
View/download PDF

15. SAT0538 Cyclophosphamide Induced Bladder Toxicity and Protective Effect of 2-Mercaptoethane Sulfonate (MESNA) in Systemic Autoimmune Disorders

Author

Yilmaz, N., primary, Emmungil, H., additional, Ozen, G., additional, Yildiz, F., additional, Dogan, I., additional, Balkarlı, A., additional, Yasar, S., additional, Pamuk, O. N., additional, Cagatay, Y., additional, Cetin, G., additional, Aksu, K., additional, Direskeneli, H., additional, Erken, E., additional, Karadag, O., additional, Cobankara, V., additional, Kasifoglu, T., additional, Sayarlıoglu, M., additional, and Yavuz, S., additional

Published
2013
Full Text
View/download PDF

17. Poster session 1: Wednesday 3 December 2014, 09:00-16:00 * Location: Poster area

Author

Tong, L, Huang, C, Ramalli, A, Tortoli, P, Luo, J, D'hooge, J, Tzemos, N, Mordi, I, Bishay, T, Bishay, T, Negishi, T, Hristova, K, Kurosawa, K, Bansal, M, Thavendiranathan, P, Yuda, S, Popescu, BA, Vinereanu, D, Penicka, M, Marwick, TH, study, SUCCOUR, Hamed, W, Kamel, MKA, Yaseen, RIY, El-Barbary, HSE, Nemes, A, Kis, O, Gavaller, H, Kanyo, E, Forster, T, Angelis, A, Vlachopoulos, C, Ioakimidis, N, Felekos, I, Chrysohoou, C, Aznaouridis, K, Abdelrasoul, M, Terentes, D, Ageli, K, Stefanadis, C, Kurnicka, K, Domienik-Karlowicz, J, Lichodziejewska, B, Goliszek, S, Grudzka, K, Krupa, M, Dzikowska-Diduch, O, Ciurzynski, M, Pruszczyk, P, Gual Capllonch, F, Lopez Ayerbe, J, Teis, A, Ferrer, E, Vallejo, N, Junca, G, Pla, R, Bayes-Genis, A, Schwaiger, JP, Knight, DS, Gallimore, A, Schreiber, BE, Handler, C, Coghlan, JG, Bruno, R M, Giardini, G, Malacrida, S, Catuzzo, B, Armenia, S, Brustia, R, Ghiadoni, L, Cauchy, E, Pratali, L, Kim, KH, Lee, KJ, Cho, JY, Yoon, HJ, Ahn, Y, Jeong, MH, Cho, JG, Park, JC, Cho, SK, Nastase, O, Enache, R, Mateescu, AD, Botezatu, D, Popescu, BA, Ginghina, C, Gu, H, Sinha, MD, Simpson, JM, Chowienczyk, PJ, Fazlinezhad, A, Tashakori Behesthi, AHMAD, Homaei, FATEME, Mostafavi, H, Hosseini, G, Bakaeiyan, M, Boutsikou, M, Petrou, E, Dimopoulos, A, Dritsas, A, Leontiadis, E, Karatasakis, G, Sahin, S T, Yurdakul, S, Yilmaz, N, Cengiz, B, Cagatay, Y, Aytekin, S, Yavuz, S, Karlsen, S, Dahlslett, T, Grenne, B, Sjoli, B, Smiseth, OA, Edvardsen, T, Brunvand, H, Nasr, G, Nasr, A, Eleraki, A, Elrefai, S, Mordi, I, Sonecki, P, Tzemos, N, Gustafsson, U, Naar, J, Stahlberg, M, Cerne, A, Capotosto, L, Rosato, E, D'angeli, I, Azzano, A, Truscelli, G, De Maio, M, Salsano, F, Terzano, C, Mangieri, E, Vitarelli, A, Renard, S, Najih, H, Mancini, J, Jacquier, A, Haentjens, J, Gaubert, JY, Habib, G, Caminiti, G, D'antoni, V, D'antoni, V, Cardaci, V, Cardaci, V, Conti, V, Conti, V, Volterrani, M, Volterrani, M, Ahn, J, Kim, DH, Lee, HO, Iliuta, L, Kim, SY, Ryu, S, Ko, CW, Pyun, YS, Yoon, SJ, Lo Iudice, F, Esposito, R, Lembo, M, Santoro, C, Ballo, PC, Mondillo, S, De Simone, G, Galderisi, M, Hwang, YM, Kim, JH, Kim, JH, Moon, KW, Yoo, KD, Kim, CM, Tagliamonte, E, Rigo, F, Cirillo, T, Caruso, A, Astarita, C, Cice, G, Quaranta, G, Romano, C, Capuano, N, Calabro', R, Zagatina, A, Zhuravskaya, N, Guseva, O, Huttin, O, Benichou, M, Voilliot, D, Venner, C, Micard, E, Girerd, N, Sadoul, N, Moulin, F, Juilliere, Y, Selton-Suty, C, Baron, T, Christersson, C, Johansson, K, Flachskampf, FA, Lee, S, Lee, J, Hur, S, Park, J, Yun, JY, Song, SK, Kim, WH, Ko, JK, Nyktari, E, Bilal, S, Ali, SA, Izgi, C, Prasad, SK, Aly, MFA, Kleijn, SAK, Kandil, HIK, Kamp, OK, Beladan, CC, Calin, A, Rosca, M, Craciun, AM, Gurzun, MM, Calin, C, Enache, R, Mateescu, A, Ginghina, C, Popescu, BA, Mornos, C, Mornos, A, Ionac, A, Cozma, D, Crisan, S, Popescu, I, Ionescu, G, Petrescu, L, Camacho, S, Gamaza Chulian, S, Carmona, R, Diaz, E, Giraldez, A, Gutierrez, A, Toro, R, Benezet, J, Antonini-Canterin, F, Vriz, O, La Carrubba, S, Poli, S, Leiballi, E, Zito, C, Careri, S, Caruso, R, Pellegrinet, M, Nicolosi, GL, Kong, W, Kyu, K, Wong, R, Tay, E, Yip, J, Yeo, TC, Poh, KK, Correia, M, Delgado, A, Marmelo, B, Correia, E, Abreu, L, Cabral, C, Gama, P, Santos, O, Rahman, MT, Borges, I P, Peixoto, ECS, Peixoto, RTS, Peixoto, RTS, Marcolla, VF, Okura, H, Kanai, M, Murata, E, Kataoka, T, Stoebe, S, Tarr, A, Pfeiffer, D, Hagendorff, A, Generati, G, Bandera, F, Pellegrino, M, Alfonzetti, E, Labate, V, Guazzi, M, Kuznetsov, VA, Yaroslavskaya, EI, Pushkarev, GS, Krinochkin, DV, Zyrianov, IP, Carigi, S, Baldazzi, F, Bologna, F, Amati, S, Venturi, P, Grosseto, D, Biagetti, C, Fabbri, E, Arlotti, M, Piovaccari, G, Rahbi, H, Bin Abdulhaq, A, Tleyjeh, I, Santoro, C, Galderisi, M, Costantino, MF, Tarsia, G, Innelli, P, Dores, E, Esposito, G, Matera, A, De Simone, G, Trimarco, B, Capotosto, L, Azzano, A, Mukred, K, Ashurov, R, Tanzilli, G, Mangieri, E, Vitarelli, A, Merlo, M, Gigli, M, Stolfo, D, Pinamonti, B, Antonini Canterin, F, Muca, M, D'angelo, GA, Scapol, S, Di Nucci, M, Sinagra, G, Behaghel, A, Feneon, D, Fournet, M, Thebault, C, Martins, RP, Mabo, P, Leclercq, C, Daubert, C, Donal, E, Davinder Pal, SINGH, Prakash Chand, NEGI, Sanjeev, ASOTRA, Rajeev, MERWAH, Ankur, DWIVED, Ram Gopal, SOOD, Mzoughi, K, Zairi, I, Jabeur, M, Ben Moussa, F, Ben Chaabene, A, Kamoun, S, Mrabet, K, Fennira, S, Zargouni, A, Kraiem, S, Demkina, AE, Hashieva, FM, Krylova, NS, Kovalevskaya, EA, Potehkina, NG, Zaroui, A, Ben Said, R, Smaali, S, Rekik, B, Ben Hlima, M, Mizouni, H, Mechmeche, R, Mourali, MS, Malhotra, A, Sheikh, N, Dhutia, H, Siva, A, Narain, R, Merghani, A, Millar, L, Walker, M, Sharma, S, Papadakis, M, Siam-Tsieu, V, Mansencal, N, Arslan, M, Deblaise, J, Dubourg, O, Zaroui, A, Rekik, B, Ben Said, R, Boudiche, S, Larbi, N, Tababi, N, Hannachi, S, Mechmeche, R, Mourali, MS, Mechmeche, R, Zaroui, A, Chalbia, T, Ben Halima, M, Rekik, B, Boussada, R, Mourali, MS, Chistyakova, M V, Govorin, AV, Radaeva, EV, Lipari, P, Bonapace, S, Valbusa, F, Rossi, A, Zenari, L, Lanzoni, L, Targher, G, Canali, G, Molon, G, Barbieri, E, Novo, G, Giambanco, S, Sutera, MR, Bonomo, V, Giambanco, F, Rotolo, A, Evola, S, Assennato, P, Novo, S, Budnik, M, Piatkowski, R, Kochanowski, J, Opolski, G, Chatzistamatiou, E, Mpampatseva Vagena, I, Manakos, K, Moustakas, G, Konstantinidis, D, Memo, G, Mitsakis, O, Kasakogias, A, Syros, P, Kallikazaros, I, Park, SM, Kim, SA, Kim, MN, Shim, WJ, Marketou, M, Parthenakis, F, Kalyva, N, Pontikoglou, CH, Maragkoudakis, S, Zacharis, E, Patrianakos, A, Maragoudakis, F, Papadaki, H, Vardas, P, Rodrigues, AC, Perandini, LA, Souza, TR, Sa-Pinto, AL, Borba, E, Arruda, AL, Furtado, M, Carvalho, F, Bonfa, E, Andrade, JL, Hlubocka, Z, Malinova, V, Palecek, T, Danzig, V, Kuchynka, P, Dostalova, G, Zeman, J, Linhart, A, Chatzistamatiou, E, Konstantinidis, D, Memo, G, Mpampatzeva Vagena, I, Moustakas, G, Manakos, K, Trachanas, K, Vergi, N, Feretou, A, Kallikazaros, I, Corut, H, Sade, LE, Ozin, B, Atar, I, Turgay, O, Muderrisoglu, H, Ledakowicz-Polak, A, Polak, L, Krauza, G, Zielinska, M, Szulik, M, Streb, W, Wozniak, A, Lenarczyk, R, Sliwinska, A, Kalarus, Z, Kukulski, T, Nogueira, MA, Branco, LM, Agapito, A, Galrinho, A, Borba, A, Teixeira, PP, Monteiro, AV, Ramos, R, Cacela, D, Cruz Ferreira, R, Guala, A, Camporeale, C, Tosello, F, Canuto, C, Ridolfi, L, Chatzistamatiou, E, Moustakas, G, Memo, G, Konstantinidis, D, Mpampatzeva Vagena, I, Manakos, K, Traxanas, K, Vergi, N, Feretou, A, Kallikazaros, I, Hristova, K, Marinov, R, Stamenov, G, Mihova, M, Persenska, S, Racheva, A, Plaskota, KJ, Trojnarska, O, Bartczak, A, Grajek, S, Ramush Bejiqi, RA, Retkoceri, R, Bejiqi, H, Beha, A, Surdulli, SH, Seya, M, Sasaoka, T, Hirasawa, K, Yoshikawa, S, Maejima, Y, Ashikaga, T, Hirao, K, Isobe, M, none, Dreyfus, J, Durand-Viel, G, Cimadevilla, C, Brochet, E, Vahanian, A, Messika-Zeitoun, D, Jin, CN, Fang, F, Meng, FX, Kam, K, Sun, JP, Tsui, GK, Wong, KK, Wan, S, Yu, CM, Lee, AP, Cho, I J, Chung, HM, Heo, R, Ha, SJ, Hong, GR, Shim, CY, Chang, HJ, Ha, JW, Chung, N, Moral, S, Gruosso, D, Galuppo, V, Teixido, G, Rodriguez-Palomares, JF, Gutierrez, L, Evangelista, A, Moral, S, Gruosso, D, Galuppo, V, Teixido, G, Rodriguez-Palomares, JF, Gutierrez, L, Evangelista, A, Moral, S, Gruosso, D, Galuppo, V, Teixido, G, Rodriguez-Palomares, JF, Gutierrez, L, Evangelista, A, Alexopoulos, Alexan, Dawson, David, Nihoyannopoulos, Petros, Zainal Abidin, H A, Ismail, JOHAN, Arshad, KAMAL, Ibrahim, ZUBIN, Lim, CW, Abd Rahman, E, Kasim, SAZZLI, Peteiro, J, Barrio, A, Escudero, A, Bouzas-Mosquera, A, Yanez, J, Martinez, D, Castro-Beiras, A, Scali, MC, Simioniuc, A, Mandoli, GE, Lombardo, A, Massaro, F, Di Bello, V, Marzilli, M, Dini, FL, Adachi, H, Tomono, J, Oshima, S, Merchan Ortega, G, Bravo Bustos, D, Lazaro Garcia, R, Sanchez Espino, AD, Macancela Quinones, JJ, Ikuta, I, Ruiz Lopez, MF, Valencia Serrano, FM, Bonaque Gonzalez, JC, Gomez Recio, M, Romano, G, D'ancona, G, Pilato, G, Di Gesaro, G, Clemenza, F, Raffa, G, Scardulla, C, Sciacca, S, Lancellotti, P, Pilato, M, Addetia, K, Takeuchi, M, Maffessanti, F, Weinert, L, Hamilton, J, Mor-Avi, V, Lang, RM, Sugano, A, Seo, Y, Watabe, H, Kakefuda, Y, Aihara, H, Nishina, H, Ishizu, T, Fumikura, Y, Noguchi, Y, Aonuma, K, Luo, XX, Fang, F, Lee, APW, Shang, Q, Yu, CM, Sammut, E C, Chabinok, R, Jackson, T, Siarkos, M, Lee, L, Carr-White, G, Rajani, R, Kapetanakis, S, Byrne, D, Walsh, JP, Ellis, L, Mckiernan, S, Norris, S, King, G, Murphy, RT, Hristova, K, Katova, TZ, Simova, I, Kostova, V, Shuie, I, Ferferieva, V, Bogdanova, V, Castelon, X, Nemes, A, Sasi, V, Domsik, P, Kalapos, A, Lengyel, C, Orosz, A, Forster, T, Grapsa, J, Demir, O, Dawson, D, Sharma, R, Senior, R, Nihoyannopoulos, P, Pilichowska, E, Zaborska, B, Baran, J, Stec, S, Kulakowski, P, Budaj, A, Herrera, J E, Palacios, I F, Mendoza, I, Marquez, J A, Herrera, J A, Octavio, J A, Dempaire, G, Rotolo, M, Kosmala, W, Kaye, G, Saito, M, Negishi, K, Marwick, TH, Maceira Gonzalez, A M, Ripoll, C, Cosin-Sales, J, Igual, B, Salazar, J, Belloch, V, Dulai, R S, Taylor, A, and Gupta, S

Abstract

Purpose: We have previously demonstrated that multi-line transmit (MLT) beam forming can provide high quality full field-of-view (90° sector) B-mode images at very high frame rates, i.e. up to 500 fps. The purpose of this study was to test the feasibility of this technique in imaging the mechanical intraventricular waves such as the one associated with activation of the left ventricle. Methods: A dedicated pulse sequence using MLT was implemented on the ULA-OP research scanner equipped with a 2.0 MHz phased array to obtain 90° sector images at a frame rate of 436 fps. The left ventricle of a healthy volunteer was imaged from the apical 4 chamber view and the RF data was acquired. Subsequently, the strain rate was extracted from the RF data using a normalized cross-correlation method. Results: As expected, during the early filling phase, myocardium lengthening (positive strain rate) was observed propagating from the base of the septum to the apex and back (Figure a). A similar wave was detected in the lateral wall, although a brief shortening (negative strain rate) was detected in the mid-wall which could be the result of reverberations (Figure b). During isovolumetric contraction, the septal wall shortened before the lateral wall (as expected) - moreover - there seemed to be an intra-wall base-apex shortening gradient (Figure c and d). Conclusions: Our preliminary results show that visualization of the cardiac mechanical activation could be feasible using MLT based high frame rate imaging. Further research is required to examine this in depth, which is the topic of on-going work. Figure Curved M-mode of strain rate

Published
2014
Full Text
View/download PDF

18. Assessment of the New 2012 EULAR/ACR Clinical Classification Criteria for Polymyalgia Rheumatica: A Prospective Multicenter Study.

Author

Ozen G, Inanc N, Unal AU, Bas S, Kimyon G, Kisacik B, Onat AM, Murat S, Keskin H, Can M, Mengi A, Cakir N, Balkarli A, Cobankara V, Yilmaz N, Yazici A, Dogru A, Sahin M, Sahin A, Gok K, Senel S, Pamuk ON, Yilmaz S, Bayindir O, Aksu K, Cagatay Y, Akyol L, Sayarlioglu M, Yildirim-Cetin G, Yasar-Bilge S, Yagci I, Aydin SZ, Alibaz-Oner F, Atagunduz P, and Direskeneli H

Subjects
Aged, Diagnosis, Differential, Female, Humans, Male, Middle Aged, Polymyalgia Rheumatica classification, Prospective Studies, Sensitivity and Specificity, Arthritis, Rheumatoid diagnosis, Polymyalgia Rheumatica diagnosis, Shoulder Pain diagnosis
Abstract

Objective: To assess the performance of the new 2012 provisional European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) polymyalgia rheumatica (PMR) clinical classification criteria in discriminating PMR from other mimicking conditions compared with the previous 5 diagnostic criteria in a multicenter prospective study., Methods: Patients older than 50 years, presenting with new-onset bilateral shoulder pain with elevated acute-phase reactants (APR), were assessed for the fulfillment of the new and old classification/diagnostic criteria sets for PMR. At the end of the 1-year followup, 133 patients were diagnosed with PMR (expert opinion) and 142 with non-PMR conditions [69 rheumatoid arthritis (RA)]. Discriminating capacity, sensitivity, and specificity of the criteria sets were estimated., Results: Discriminating capacity of the new clinical criteria for PMR from non-PMR conditions and RA as estimated by area under the curve (AUC) were good with AUC of 0.736 and 0.781, respectively. The new criteria had a sensitivity of 89.5% and a specificity of 57.7% when tested against all non-PMR cases. When tested against all RA, seropositive RA, seronegative RA, and non-RA control patients, specificity changed to 66.7%, 100%, 20.7%, and 49.3%, respectively. Except for the Bird criteria, the 4 previous criteria had lower sensitivity and higher specificity (ranging from 83%-93%) compared with the new clinical criteria in discriminating PMR from all other controls., Conclusion: The new 2012 EULAR/ACR clinical classification criteria for PMR is highly sensitive; however, its ability to discriminate PMR from other inflammatory/noninflammatory shoulder conditions, especially from seronegative RA, is not adequate. Imaging and other modifications such as cutoff values for APR might increase the specificity of the criteria.

Published
2016
Full Text
View/download PDF

19. Response rate of initial conventional treatments, disease course, and related factors of patients with adult-onset Still's disease: Data from a large multicenter cohort.

Author

Kalyoncu U, Solmaz D, Emmungil H, Yazici A, Kasifoglu T, Kimyon G, Balkarli A, Bes C, Ozmen M, Alibaz-Oner F, Erten S, Cagatay Y, Cetin GY, Yilmaz S, Yildiz F, Pamuk ON, Kucuksahin O, Kilic L, Yazisiz V, Karadag O, Koca SS, Hayran M, Akar S, Aksu K, Akkoc N, Keser G, Gonullu E, Kisacik B, Onat AM, Soy M, Inanc N, Direskeneli H, Sayarlioglu M, Erken E, Turgay M, Cefle A, Ertenli I, and Pay S

Subjects
Adolescent, Adult, Aged, Aged, 80 and over, Anti-Inflammatory Agents therapeutic use, Biomarkers, Delayed Diagnosis, Drug Therapy, Combination, Female, Humans, Male, Middle Aged, Phenotype, Recurrence, Remission Induction, Risk Factors, Treatment Outcome, Young Adult, Still's Disease, Adult-Onset diagnosis, Still's Disease, Adult-Onset therapy
Abstract

Background: Adult-onset Still's disease (AOSD) is a rare condition, and treatment choices are frequently dependent on expert opinions. The objectives of the present study were to assess treatment modalities, disease course, and the factors influencing the outcome of patients with AOSD., Methods: A multicenter study was used to reach sufficient patient numbers. The diagnosis of AOSD was based on the Yamaguchi criteria. The data collected included patient age, gender, age at the time of diagnosis, delay time for the diagnosis, typical AOSD rash, arthralgia, arthritis, myalgia, sore throat, lymphadenopathy, hepatomegaly, splenomegaly, pleuritis, pericarditis, and other rare findings. The laboratory findings of the patients were also recorded. The drugs initiated after the establishment of a diagnosis and the induction of remission with the first treatment was recorded. Disease patterns and related factors were also investigated. A multivariate analysis was performed to assess the factors related to remission., Results: The initial data of 356 patients (210 females; 59%) from 19 centers were evaluated. The median age at onset was 32 (16-88) years, and the median follow-up time was 22 months (0-180). Fever (95.8%), arthralgia (94.9%), typical AOSD rash (66.9%), arthritis (64.6%), sore throat (63.5%), and myalgia (52.8%) were the most frequent clinical features. It was found that 254 of the 306 patients (83.0%) displayed remission with the initial treatment, including corticosteroids plus methotrexate with or without other disease-modifying antirheumatic drugs. The multivariate analysis revealed that the male sex, delayed diagnosis of more than 6 months, failure to achieve remission with initial treatment, and arthritis involving wrist/elbow joints were related to the chronic disease course., Conclusion: Induction of remission with initial treatment was achieved in the majority of AOSD patients. Failure to achieve remission with initial treatment as well as a delayed diagnosis implicated a chronic disease course in AOSD., (Copyright © 2016 Elsevier Ltd. All rights reserved.)

Published
2016
Full Text
View/download PDF

20. Investigation of the association between Rho/Rho-kinase gene polymorphisms and systemic sclerosis.

Author

Pehlivan Y, Yolbas S, Cetin GY, Alibaz-Oner F, Cagatay Y, Yilmaz N, Oztuzcu S, Donmez S, Ozgen M, Koca SS, Pamuk ON, Sayarlıoglu M, Kisacik B, Direskeneli H, Demiryurek AT, and Onat AM

Subjects
Adult, Case-Control Studies, Chi-Square Distribution, Female, Gene Frequency, Genetic Association Studies, Genetic Predisposition to Disease, Haplotypes, Humans, Male, Middle Aged, Phenotype, Risk Factors, Scleroderma, Systemic diagnosis, Turkey, rhoC GTP-Binding Protein, Polymorphism, Single Nucleotide, Scleroderma, Systemic genetics, rho GTP-Binding Proteins genetics, rho-Associated Kinases genetics, rhoA GTP-Binding Protein genetics
Abstract

Systemic sclerosis (SSc) is a disease characterized by inflammation, vascular abnormalities and fibrosis. The role of Rho/Rho-kinase pathway was demonstrated in the pathogenesis of fibrosis, inflammation and vascular abnormalities. This study was aimed to investigate the relation between SSc and Rho/Rho-kinase gene polymorphisms. The study included 339 patients with SSc and 302 healthy subjects who were apparently healthy and at similar age and gender. Genotype distributions and allele frequencies were detected by using Chi-square test or Fisher's exact Chi-square test between groups, and the haplotype analysis was applied using online program (SHEsis). Significant association was found in a polymorphism in the ROCK1 gene (rs35996865), a polymorphism in ROCK2 gene (rs10178332), a polymorphism in RhoA gene (rs2177268) and two polymorphisms in RhoC gene (rs11102522 and rs11538960) with SSc disease (p < 0.0022). In this study, association between SSc disease and Rho/Rho-kinase gene polymorphisms was investigated for the first time; significant associations between ROCK1, ROCK2, RhoA and RhoC gene polymorphisms and SSc disease were demonstrated. The results strongly suggest that this SNP may be an important risk factor for development of SSc. However, further validation of these findings in an independent cohort is necessary.

Published
2016
Full Text
View/download PDF

21. Association of TRPM Channel Gene Polymorphisms with Systemic Sclerosis.

Author

Oztuzcu S, Onat AM, Pehlivan Y, Alibaz-Oner F, Donmez S, Cetin GY, Yolbas S, Bozgeyik I, Yilmaz N, Ozgen M, Cagatay Y, Kisacik B, Koca SS, Pamuk ON, Sayarlioglu M, Direskeneli H, and Demiryurek AT

Subjects
Adult, Female, Gene Frequency, Genetic Predisposition to Disease, Genotype, Haplotypes, Humans, Male, Middle Aged, Polymorphism, Single Nucleotide, Scleroderma, Systemic pathology, Turkey, Genetic Association Studies, Scleroderma, Systemic genetics, TRPM Cation Channels genetics
Abstract

Background/aim: Systemic sclerosis (SSc) is an inflammatory disease characterized by vascular abnormalities and fibrosis. The aim of the present study was to investigate the possible role of transient receptor potential melastatin (TRPM) channel genes in the susceptibility and phenotype expression of SSc., Materials and Methods: A total of 339 patients with SSc and 302 healthy controls were studied. Genomic DNA was extracted from leukocytes of the peripheral blood, and 25 single nucleotide polymorphisms in the TRPM channel genes were analyzed by the BioMark HD dynamic array system., Results: There were marked increases in the CC genotype (94.7% vs 81.8%, p<0.0001) and C allele frequencies (97.0% vs. 90.1%, p<0.0001) in the TRPM3 rs1328142, and TT genotype (19.0% vs. 7.8%, p=0.0002) in TRPM5 rs34551253 (Ala456Thr) polymorphism in SSc patients when compared to controls. TRPM3 gene rs1328142 polymorphism was also markedly associated with disease phenotype. However, no associations with the other 23 polymorphisms studied were found., Conclusion: This is the first study to examine the involvement of TRPM channel gene variations on the risk of SSc incidence. Our results suggest roles of TRPM3 and TRPM5 gene variants in the susceptibility to or clinical expression of SSc in the Turkish population., (Copyright © 2015 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved.)

Published
2015

22. Incidence of Cyclophosphamide-induced Urotoxicity and Protective Effect of Mesna in Rheumatic Diseases.

Author

Yilmaz N, Emmungil H, Gucenmez S, Ozen G, Yildiz F, Balkarli A, Kimyon G, Coskun BN, Dogan I, Pamuk ON, Yasar S, Cetin GY, Yazici A, Ergulu Esmen S, Cagatay Y, Yilmaz S, Cefle A, Sayarlioglu M, Kasifoglu T, Karadag O, Pehlivan Y, Dalkilic E, Kisacik B, Cobankara V, Erken E, Direskeneli H, Aksu K, and Yavuz S

Subjects
Adult, Aged, Cyclophosphamide therapeutic use, Cystitis chemically induced, Female, Humans, Incidence, Male, Middle Aged, Treatment Outcome, Cyclophosphamide adverse effects, Cystitis epidemiology, Mesna therapeutic use, Protective Agents therapeutic use, Rheumatic Diseases drug therapy
Abstract

Objective: To assess bladder toxicity of cyclophosphamide (CYC) and uroprotective effect of mesna in rheumatic diseases., Methods: Data of 1018 patients (725 women/293 men) treated with CYC were evaluated in this retrospective study. All of the following information was obtained: the cumulative CYC dose, route of CYC administration, duration of therapy, concomitant mesna usage, and hemorrhagic cystitis. Cox proportional hazard model was used for statistics., Results: We identified 17 patients (1.67%) with hemorrhagic cystitis and 2 patients (0.19%) with bladder cancer in 4224 patient-years. The median time for diagnosis to hemorrhagic cystitis was 10 months (4-48) and bladder cancer was 8 years (6-10.9). There were 583 patients (57.2%) who received mesna with intravenous CYC therapy. We observed similar incidence rate for hemorrhagic cystitis in both patient groups concomitantly treated with or without mesna [9/583 (1.5%) vs 8/425 (1.8%) respectively, p = 0.08]. Cumulative CYC dose (HR for 10-g increments 1.24, p < 0.001) was associated with hemorrhagic cystitis., Conclusion: Cumulative dose was the only risk factor for hemorrhagic cystitis in patients treated with CYC. No proof was obtained for the uroprotective effect of mesna in our cohort.

Published
2015
Full Text
View/download PDF

23. The rate and significance of type 1/type 2 serum amyloid A protein gene polymorphisms in patients with ankylosing spondylitis and amyloidosis.

Author

Yildirim Cetin G, Ganiyusufoglu E, Solmaz D, Cagatay Y, Yılmaz Oner S, Erer B, Sagliker HS, Avci AB, Akar S, Pamuk ON, Kılınc M, Kasifoglu T, Direskeneli H, Gul A, and Sayarlioglu M

Subjects
Adult, Alleles, Amyloidosis complications, Amyloidosis pathology, Creatinine blood, Cytoskeletal Proteins genetics, Familial Mediterranean Fever complications, Familial Mediterranean Fever pathology, Female, Gene Expression, Gene Frequency, Humans, Male, Middle Aged, Proteinuria pathology, Proteinuria urine, Pyrin, Spondylitis, Ankylosing complications, Spondylitis, Ankylosing pathology, Amyloidosis genetics, Familial Mediterranean Fever genetics, Mutation, Polymorphism, Single Nucleotide, Serum Amyloid A Protein genetics, Spondylitis, Ankylosing genetics
Abstract

A relationship between the presence of amyloidosis and SAA1 genotype has been shown in recent studies of (principally) familial Mediterranean fever patients. We found that the SAA1 rs12218 polymorphism was significantly more prevalent in ankylosing spondylitis patients with amyloidosis.

Published
2015
Full Text
View/download PDF

24. Behçet's disease: immunological relevance with arthritis of ankylosing spondylitis.

Author

Aktas Cetin E, Cosan F, Kucuksezer UC, Bilgic S, Cagatay Y, Gul A, and Deniz G

Subjects
Adult, Flow Cytometry, HLA-DR Antigens analysis, Humans, Interferon-gamma biosynthesis, Interleukin-12 biosynthesis, Interleukin-2 Receptor alpha Subunit analysis, Synovial Fluid immunology, Th1 Cells immunology, Th2 Cells immunology, Behcet Syndrome immunology, Spondylitis, Ankylosing immunology
Abstract

Behçet's disease (BD) is a multi-system inflammatory disorder, in which cytokine balance is polarized to Th1. In this study, the cell surface molecule expression, Th1/Th2, inflammatory cytokine levels in blood, and synovial fluid of CD3(+) T lymphocytes in BD were investigated. The study group consisted of 10 BD, 10 ankylosing spondylitis (AS) patients with peripheral arthritis, and 10 healthy subjects. Expression of cell surface molecules, intracellular IL-2, IL-5, IL-8, IL-10, IL-12, IFN-γ, and TNF-α levels in CD3(+) T lymphocytes were determined by flow cytometry in synovial and peripheral blood mononuclear cells (PBMCs). Synovial and plasma cytokine levels were measured by ELISA and CBA. In PBMCs, CD4, CD25, HLA-DR expression and intracellular IL-12, and TNF-α levels of CD3(+) T lymphocytes were statistically increased in BD patients compared to healthy subjects. Compare to AS patients, CD25 and HLA-DR surface expression and intracellular IFN-γ and TNF-α levels in T cells were significantly elevated in BD patients. In BD patients, there was an increase in IL-8 secretion; however, in AS patients, both Th1- and Th2-type cytokines were increased compare to healthy subjects. Intracellular cytokine expression did not show any difference in BD patients; however, IL-12 content of synovial fluid was significantly increased compared to AS patients. Our findings revealed that Th1 polarization occurred in both peripheral blood and synovial fluid of BD patients with arthritis. It is found no difference between synovial fluid analysis of BD and AS patients, showing the similarities in the pathogenesis of both diseases.

Published
2013
Full Text
View/download PDF

25. Human immunodeficiency virus and avascular necrosis of the femoral head: a case report.

Author

Caĝatay AA, Kücükkaya R, Akyildiz M, Berk H, Cagatay Y, Yildirmak T, Ozsüt H, Eraksoy H, and Calangu S

Subjects
Adult, Antibodies, Anticardiolipin blood, Antiretroviral Therapy, Highly Active, Female, HIV Infections drug therapy, HIV Infections immunology, Humans, Femur Head Necrosis etiology, HIV Infections complications
Published
2004

26. Extrapulmonary tuberculosis in immunocompetent adults.

Author

Cagatay AA, Caliskan Y, Aksoz S, Gulec L, Kucukoglu S, Cagatay Y, Berk H, Ozsut H, Eraksoy H, and Calangu S

Subjects
Adolescent, Adult, Aged, Aged, 80 and over, Antitubercular Agents therapeutic use, Female, Humans, Incidence, Male, Middle Aged, Retrospective Studies, Risk Factors, Severity of Illness Index, Tuberculosis, Lymph Node diagnosis, Tuberculosis, Lymph Node physiopathology, Tuberculosis, Meningeal diagnosis, Tuberculosis, Meningeal physiopathology, Turkey epidemiology, Immunocompetence, Tuberculosis, Lymph Node etiology, Tuberculosis, Meningeal etiology, Tuberculosis, Pulmonary complications
Abstract

Tuberculosis continues to be a significant cause of morbidity and mortality. Although tuberculosis usually attacks the lungs, other organs can also be affected, leading to extrapulmonary tuberculosis (EPT) or disseminated tuberculosis. This study retrospectively analysed the incidence, clinical sites and risk factors for EPT in 252 patients with EPT between 1 January 1991 and 30 June 2003. EPT was defined as clinical, laboratory, imaging, and/or histopathological evidence of mycobacterial infection in a site other than hilar lymph nodes or lung parenchyma. In our study group, tuberculous lymphadenitis (36.5%) was found to be the most common clinical presentation of EPT. 119 (47.2%) patients developed the severe form of EPT, according to the WHO report, and 133 (52.8%) patients developed the less severe form. A case history of pulmonary tuberculosis was found to be a risk factor for the development of EPT (p <0.05). The study showed that EPT is still a public health problem. These findings suggested that pulmonary tuberculosis may play a critical role in the development of EPT. 12-month therapy may be chosen in patients with EPT considering acceptable adverse effects without relapses.

Published
2004
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results